Pharmacokinetic drug interactions occur when one drug alters the absorption, distribution, metabolism, or elimination of another, leading to changes in the concentration of the affected drug at its site of action. These interactions are predictable and dose-dependent, and they represent a major cause of adverse drug reactions, therapeutic failure, and drug-related hospitalizations. Understanding the mechanisms underlying pharmacokinetic interactions enables clinicians to anticipate, prevent, and manage them effectively.
Absorption interactions affect the rate or extent of drug entry into the systemic circulation. Chelation complexes form when certain drugs bind to each other in the gastrointestinal tract, preventing absorption of one or both agents. Fluoroquinolone and tetracycline antibiotics chelate with divalent and trivalent cations found in antacids, iron supplements, and dairy products, reducing antibiotic bioavailability by up to 90 percent. Staggering administration by at least two hours can mitigate this interaction. Food effects alter drug absorption: high-fat meals increase the absorption of lipophilic drugs such as griseofulvin and isotretinoin while decreasing absorption of others such as alendronate. pH-dependent absorption occurs when drugs that require an acidic environment for dissolution, such as ketoconazole, are co-administered with proton pump inhibitors, which reduce gastric acidity and impair absorption.
Distribution interactions most commonly involve protein binding displacement. Many drugs bind to plasma proteins, primarily albumin, and only the unbound fraction is pharmacologically active. When two highly protein-bound drugs are co-administered, one may displace the other from protein binding sites, transiently increasing the free concentration of the displaced drug. This mechanism was historically overemphasized; clinically significant interactions generally require the displaced drug to have a narrow therapeutic index, a small volume of distribution, and rapid elimination. The classic example is the interaction between warfarin and phenylbutazone, where displacement of warfarin from albumin increases its anticoagulant effect precipitously.
Metabolism interactions are the most clinically important category and predominantly involve the cytochrome P450 (CYP) enzyme system. Enzyme induction occurs when a drug increases the production or activity of CYP enzymes, accelerating the metabolism of co-administered drugs and reducing their efficacy. Rifampin is a potent inducer of CYP3A4, CYP2C9, and CYP2C19 and can reduce the plasma concentrations of oral contraceptives, warfarin, and many antiretroviral agents to subtherapeutic levels. Enzyme inhibition occurs when a drug decreases the activity of CYP enzymes, slowing the metabolism of co-administered drugs and increasing their concentrations, potentially to toxic levels. The interaction between warfarin and azole antifungals illustrates this: fluconazole inhibits CYP2C9, reducing warfarin clearance and substantially increasing the international normalized ratio and bleeding risk.
Elimination interactions affect renal or biliary excretion of drugs. Competitive inhibition of renal tubular secretion occurs when two drugs utilize the same active transport system in the proximal tubule. Probenecid was historically used therapeutically to reduce penicillin elimination by inhibiting organic anion transporters. Methotrexate and NSAIDs compete for renal tubular secretion, and co-administration can lead to methotrexate accumulation and severe toxicity. Alterations in urinary pH can affect the passive reabsorption of weak acids and bases. Alkalinization of urine with sodium bicarbonate increases the elimination of weak acids such as salicylates and phenobarbital, a principle exploited in the management of poisoning.
Clinical examples of significant pharmacokinetic interactions include the statin-grapefruit juice interaction, where grapefruit juice irreversibly inhibits intestinal CYP3A4, increasing the bioavailability of simvastatin and lovastatin and raising the risk of myopathy and rhabdomyolysis. The warfarin-azole interaction through CYP2C9 inhibition can produce life-threatening bleeding. The contraceptive-rifampin interaction, where rifampin induces CYP3A4-mediated metabolism of ethinylestradiol, has led to unintended pregnancies.
Management strategies for pharmacokinetic interactions include avoiding the combination when possible, adjusting doses based on expected changes in drug concentrations, separating administration times for absorption interactions, selecting alternative drugs without interaction potential, and monitoring drug concentrations or clinical effects more frequently when combinations cannot be avoided.
